Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FD Technologies Ltd. Share Issue/Capital Change 2018

Aug 31, 2018

6234_sha_2018-08-31_b651b760-5f26-4ce5-ac50-a6267cd5d358.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4604Z

First Derivatives PLC

31 August 2018

31 August 2018

First Derivatives plc

("FD" or the "Company")

Issue of Equity

FD (AIM: FDP.L, ESM: FDP.I) announces the issue and allotment of 90,000 new ordinary shares of 0.5p each in the Company (the "Ordinary Shares") pursuant to the exercise of share options by certain employees.

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and ESM and it is expected that admission will take place on 7 September 2018. The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following these allotments, the total issued share capital of the Company will increase to 25,981,858 ordinary shares.

Enquiries

For further information please contact:

First Derivatives plc

Brian Conlon, Chief Executive Officer

Graham Ferguson, Chief Financial Officer

Ian Mitchell, Head of Investor Relations
+44(0)28 3025 2242

www.firstderivatives.com
Investec Bank plc (Nominated Adviser and Broker)

Andrew Pinder

Carlton Nelson

Sebastian Lawrence
+44 (0)20 7597 5970
Goodbody (ESM Adviser and Broker)

Linda Hickey

Finbarr Griffin
+353 1 667 0420

For further information, please visit www.firstderivatives.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

IOEFKDDBQBKDQFN